Study: Gender-Affirming Care for Transgender Youth in US Far Less Common Than Perceived
A new analysis of nearly 5.2 million US adolescents (2018-2022) shows that prescriptions of puberty blockers and gender-affirming hormones for transgender youth are rare; only 20.81 per 100,000 biologically female teens received puberty blockers, and 49.9 per 100,000 received hormones, challenging p...
Study: Gender-Affirming Care for Transgender Youth in US Far Less Common Than Perceived
A new analysis of nearly 5.2 million US adolescents (2018-2022) shows that prescriptions of puberty blockers and gender-affirming hormones for transgender youth are rare; only 20.81 per 100,000 biologically female teens received puberty blockers, and 49.9 per 100,000 received hormones, challenging p...
Progress
40% Bias Score
UK Bans Puberty Blockers for Minors Amidst Growing European Concerns
The United Kingdom has banned puberty blockers for children under 18, joining other Western European nations restricting access amid concerns about long-term effects and insufficient evidence of efficacy; this follows a temporary ban and challenges the previously accepted "Dutch protocol."
UK Bans Puberty Blockers for Minors Amidst Growing European Concerns
The United Kingdom has banned puberty blockers for children under 18, joining other Western European nations restricting access amid concerns about long-term effects and insufficient evidence of efficacy; this follows a temporary ban and challenges the previously accepted "Dutch protocol."
Progress
52% Bias Score
UK Indefinitely Bans Puberty Blockers for Under-18s
The UK government has indefinitely banned puberty blockers for under-18s with gender dysphoria due to safety concerns raised by the Commission on Human Medicines and the Cass Review, impacting access to these treatments across the UK and prompting a future clinical trial.
UK Indefinitely Bans Puberty Blockers for Under-18s
The UK government has indefinitely banned puberty blockers for under-18s with gender dysphoria due to safety concerns raised by the Commission on Human Medicines and the Cass Review, impacting access to these treatments across the UK and prompting a future clinical trial.
Progress
60% Bias Score
Court to Maintain Oversight of Teen's Cross-Sex Hormone Case
A UK Court of Appeal ruled that it will continue to oversee a case involving a 16-year-old seeking cross-sex hormones, despite the child's capacity to consent, due to concerns about rapidly changing regulations and potential future disagreements. This follows a lower court's dismissal of the mother'...
Court to Maintain Oversight of Teen's Cross-Sex Hormone Case
A UK Court of Appeal ruled that it will continue to oversee a case involving a 16-year-old seeking cross-sex hormones, despite the child's capacity to consent, due to concerns about rapidly changing regulations and potential future disagreements. This follows a lower court's dismissal of the mother'...
Progress
44% Bias Score
U.K. Indefinitely Bans New Puberty Blocker Prescriptions for Transgender Minors
The U.K. indefinitely banned new puberty blocker prescriptions for transgender minors due to insufficient evidence of benefits and safety concerns, following an independent review; existing users can continue treatment, and the ban will be revisited in 2027.
U.K. Indefinitely Bans New Puberty Blocker Prescriptions for Transgender Minors
The U.K. indefinitely banned new puberty blocker prescriptions for transgender minors due to insufficient evidence of benefits and safety concerns, following an independent review; existing users can continue treatment, and the ban will be revisited in 2027.
Progress
60% Bias Score